日期: 2026 年 6 月 16 日

MINNEAPOLIS, MN, June 17, 2026 - (ACN Newswire via SeaPRwire.com) - Air T, Inc. (NASDAQ:AIRT) today announced that its majority owned business Crestone Air Partners, a global aviation asset management platform, has completed its acquisition of Arena Aviation Capital - a well-established aviation asset manager with a diversified portfolio and deep airline relationships. The transaction, first disclosed on March 8, 2026, has now closed following the satisfaction of all customary closing conditions and required approvals.The acquisition materially expands Crestone. Assets under management (AUM) as of December 31, 2025, were $800 million; as of March 31, 2026, AUM had grown to $1.2 billion; and post-transaction, the combined platform now comprises $3.6 billion of AUM. Crestone receives standard aviation industry management fees, including origination fees, administrative fees, disposition fees, and an incentive fee above a certain hurdle rate (which varies by investment transaction). Our aviation asset management platforms seek to generate 10%+ returns after fees.Immediately prior to the closing, Air T owned 90% of the common interests in Crestone Asset Management, LLC ("CAM"). At this same time, entities controlled by the Mill Road Investors collectively owned the remaining 10% of the common interests in CAM. In connection with the transactions, Air T and Aviation Growth Initiatives, LLC ("AGI"), a management-affiliated entity formed by executives of Crestone Air Partners, Inc., acquired the MRC Parties' 10% common interest position in CAM at a pre-money valuation of $62 million for aggregate cash consideration of $6.2 million. In connection with the reorganization, the parties also amended CAM's limited liability company agreement to reflect the exit of the MRC parties from the common interest holder group.On the closing date, Blue Owl Capital bought in to Crestone Air Partners at an $80 million valuation post-merger for up to 12.5% of Crestone Air Partners, dependent upon Crestone performance. Air T now owns approximately 83.9% of the equity of this business.This transaction is a clear expression of how Air T invests. We are a permanent capital vehicle - buying to build, not to trade - and we give the leaders of our businesses the runway and resources to grow on their own terms."We buy to build and empower dynamos and dynamic teams. Our investments don't come with expiration dates," said Nick Swenson, Chief Executive Officer of Air T, Inc. "Crestone has grown from zero to over $3.5 billion dollars in assets under management in five years. Our job was to provide permanent capital and the runway, then let Crestone build. Crestone's leasing capabilities are supported by the AirT network: airframe and engine material sales, landing gear leasing, disassembly, storage, and MRO facilities all sit inside the Air T family. Crestone can draw on every one of them across an aircraft's life. Aviation has a lot of niche, high-value businesses within it, and we seek to know them well. That's the momentum a networked portfolio creates - and we intend to keep at it."For additional information on the transaction, please refer to the Crestone Air Partners Press Release.NOTE REGARDING STAKEHOLDER QUESTIONSIf you have questions related to this release or other Air T matters, please use our interactive Q&A capability, through Slido.com, accessible from our website, to submit your questions. We intend to keep that link open and available for shareholder questions. Questions submitted through Slido will be answered "live" and in writing at our Annual Meeting, and via a written response on a quarterly basis. Note that legal and pragmatic requirements restrict us from answering every question posted, yet we intend to address all reasonable and relevant questions with a written answer.ABOUT AIR T, INC.Established in 1980, Air T Inc. is a portfolio of powerful businesses and financial assets, each of which is independent yet interrelated. Its core segments are overnight air cargo, ground support equipment, commercial aircraft, engines and parts, regional airline and digital solutions. We seek to expand, strengthen and diversify Air T's after-tax cash flow per share. Our goal is to build Air T's core businesses, and when appropriate, to expand into adjacent and other industries. We seek to activate growth and overcome challenges while delivering meaningful value for all stakeholders. For more information, visit www.airt.com. The information on our website is available for information purposes only and is not incorporated by reference into this press release.CONTACTTracy Kennedy, Chief Financial Officertkennedy@airt.comSOURCE: Air T, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 16, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) is celebrating its 60th anniversary this year with a series of commemorative events. Two key events – the Next 60 Forum and 60th Anniversary Cocktail Reception – were held today, attracting over 1,000 guests from the political and business sectors. HKTDC Chairman Prof Frederick Ma personally invited several former Chairmen, including Dr Victor Fung, Peter Woo, Jack So and Vincent Lo, to serve as forum guests, while he himself served as the moderator. Together, they reviewed how the HKTDC has developed and looked ahead to future opportunities. Secretary for Justice of the Hong Kong Special Administrative Region (HKSAR), Paul Lam, officiated at the reception and joined leaders from various sectors in witnessing this important milestone.Prof Frederick Ma, Chairman of the HKTDC, said: "This forum brings together an accumulated 480 years of experience and wisdom of several former Chairmen. We will build on the past and pave the way for the future, charting a new development outlook for Hong Kong. Under 'One Country, Two Systems', Hong Kong is guided by national development and is globally responsive, providing a strong foundation for progress. The HKTDC will continue to assist enterprises going global, deepen international exchange, strengthen industry connections, and facilitate substantive cooperation."The Next 60 Forum centred on the theme of "Retrospect and Prospect". Former Chairman Baroness Dunn kicked off the forum with a pre-recorded address. Participants reviewed Hong Kong's economic transformation from a manufacturing base into an international financial and trading hub, and explored how Hong Kong can continue to play its role as a superconnector and super value-adder in an evolving global landscape.The 60th Anniversary Cocktail Reception held in the evening of the same day was attended by Secretary for Justice of the HKSAR Paul Lam, Deputy Commissioner of the Office of the Commissioner of the Ministry of Foreign Affairs of the People’s Republic of China in the HKSAR Li Yongsheng, Director-General of the Economic Affairs Department of the Liaison Office of the Central People's Government in the HKSAR Xu Weigang, President of the Legislative Council Starry Lee, and a number of HKSAR government officials, including Deputy Financial Secretary Michael Wong, Secretary for Culture, Sports and Tourism Rosanna Law, and Acting Secretary for Financial Services and the Treasury Joseph Chan. Also in attendance were former HKTDC Chairmen Victor Fung, Peter Woo, Jack So and Vincent Lo, former Executive Directors Fred Lam and Margaret Fong, current Executive Director Sophia Chong, as well as current and former Council Members.Prof Ma said: "Right before this reception, I had a lively dialogue with the HKTDC’s former Chairmen who shared their vision for the Council and Hong Kong in the coming decades. Let me tell you: the future looks bright. In spite of global challenges, I firmly believe that Hong Kong remains a beacon of hope. The HKTDC has always evolved alongside Hong Kong, our growth mirroring our city’s progress. And just like Hong Kong, the HKTDC has remained resilient, which I know will see us through the next 60 years."Secretary for Justice of the HKSAR Paul Lam said in his address at the Reception: "For 60 years, the Government’s policy priorities coupled the steadfast support combined with the TDC’s global network and on-the-ground expertise. Together, we have advanced Hong Kong’s trade and economic development. And together, we are building Hong Kong’s flourishing future. In Chinese culture, 60 years represents the completion of a full cycle – it does not mark an end, but a beginning of new cycle. It reminds us that after six decades of growth, wisdom and achievements, the time has come to welcome a new, and even more successful chapter."Looking ahead, the HKTDC will seize opportunities arising from the country's 15th Five-Year Plan, support the Government's initiatives, and assist mainland enterprises in expanding overseas. It will also provide more comprehensive support tailored to the evolving needs of five major industry clusters, namely: Finance and Professional Services; Global Network and Supply Chain; Technology and Digital Innovation; Wellness and Creative Industries; and Consumer Goods and Lifestyle.Photo download: https://bit.ly/4otc10KHKTDC Chairman Prof Frederick Ma delivers the opening address at the Next 60 Forum, reviewing the development of the HKTDC and Hong Kong over the past 60 years and looking ahead to future opportunitiesHKTDC Chairman Prof Frederick Ma exchanges views with several former Chairmen at the Next 60 Forum, sharing experience and insights, and exploring the outlook for Hong Kong and the HKTDC. (From left: HKTDC Chairman Prof Frederick Ma, former Chairmen Dr Victor Fung, Peter Woo, Jack So and Vincent Lo)Secretary for Justice of the HKSAR Paul Lam delivers an address at the 60th Anniversary Cocktail Reception, joining various sectors in witnessing this important milestone for the HKTDCHKTDC Chairman Prof Frederick Ma toasts with several official guests at the reception. (From left: Former HKTDC Chairmen Vincent Lo and Peter Woo, Deputy Commissioner of the Office of the Commissioner of the Ministry of Foreign Affairs of the People’s Republic of China in the HKSAR Li Yongsheng, Secretary for Justice of the HKSAR Paul Lam, HKTDC Chairman Prof Frederick Ma, former HKTDC Chairmen Dr Victor Fung and Jack So, HKTDC Executive Director Sophia Chong)The 60th Anniversary Cocktail Reception brings together representatives from the political and business sectors, creating a grand occasionGuests visit 60th Anniversary Thematic Exhibition, tracing the development of Hong Kong and the HKTDC over the past 60 yearsWebsitesHKTDC’s 60th Anniversary Exhibition Zone: https://bit.ly/4ovwn9GHKTDC’s 60th Anniversary Celebration Activities: https://60.hktdc.com/enHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesHKTDC’s Communications & Public Affairs Department:Stanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgNavin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgWinnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 16, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (“Dimerix”), for the development and commercialization of DMX-200 in Greater China (Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan region), South Korea and certain Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam and Philippines). This collaboration will further strengthen Everest’s nephrology product portfolio and pipeline synergy, reinforce the company’s strategic position in kidney and autoimmune diseases.Under the terms of the agreement, Everest will pay Dimerix a US$ 10 million upfront payment, and up to US$30 million potential success-based development and regulatory milestone payments, as well as up to US$300 million in commercial milestone payments. In addition, Everest will pay tiered royalties between 10-15% of DMX-200 net sales in Greater China, South Korea, and certain Southeast Asian countries.DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal, Phase 3 study, ACTION3, for the treatment of Focal Segmental Glomerulosclerosis (FSGS). Public disclosures show that DMX-200 has received Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).“This collaboration with Dimerix marks an important step in advancing our strategic focus in kidney disease and further strengthening our innovative renal portfolio,” said Yifang Wu, Chairman of the Board of Everest Medicines. “Patients with FSGS in China have long faced significant unmet medical needs due to the lack of targeted treatment options. The positive interim results from the global pivotal Phase 3 study of DMX-200 underscore its potential to offer a meaningful new therapy for these patients. Leveraging our proven expertise in clinical development and commercialization, we are committed to accelerating access to DMX-200 in China and beyond and exploring other glomerulopathies. We look forward to working closely with Dimerix to bring this innovative therapy to more patients in need.”Dr Nina Webster, Chief Executive Officer and Managing Director of Dimerix, said: “We are delighted to establish this partnership with Everest Medicines, a company with strong rare renal disease expertise and a proven track record in commercializing in Greater China, South Korea and certain Southeast Asian countries. Importantly, this collaboration significantly expands the potential reach of DMX-200 into a large and underserved patient population. Everest is well positioned to maximize the opportunity in the licensed regions, while allowing Dimerix to retain focus on progressing our global registrational program, delivering value for shareholders and providing real hope for patients with FSGS across the globe in need of treatment options.”FSGS is a rare, serious kidney disorder characterized by progressive scarring (sclerosis) in parts of the glomeruli—the kidney’s filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. In China, 500,000 to 1 million people are estimated to be living with FSGS, including both adults and children1,2.The ACTION3 study, which is titled “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis”, is a pivotal (Phase 3), multi-centre, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients will be randomized to receive either DMX-200 (120 mg capsule twice daily) or placebo. The single Phase 3 trial in FSGS patients has two interim analysis points built in that are designed to capture evidence of proteinuria and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval.The ACTION3 study has completed enrollment of 333 patients. In early 2024, Dimerix reported positive interim results from the ACTION3 trial in FSGS, showing DMX-200 was performing better than placebo in reducing proteinuria at that time. There have been no safety concerns to date following 8 reviews by the independent data monitoring committee, the most recent in June 2026. In April 2026, an external statistical blinded review of ACTION3 data achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial’s conclusion.Rather than a single product licensing deal, this collaboration is viewed by the industry as a significant step forward for Everest Medicines in deepening its layout in the nephrology field. In recent years, the company has continuously built a nephrology product matrix including Nefecon®, civorebrutinib (EVER001), MT1013, and Bejescin® (MIL62), focusing on areas such as IgA nephropathy and chronic kidney disease (CKD). The introduction of DMX-200 is not only expected to fill the gap in innovative treatments for FSGS in China, but will also further enrich Everest Medicines’ nephrology pipeline, creating synergies with existing products and R&D projects to extend its footprint into the broader CKD sector.Meanwhile, this partnership covers multiple core markets, including Greater China, South Korea, and Southeast Asia, further reflecting Everest Medicines’ strategic direction to continuously refine its commercialization network across the Asia-Pacific region. With a massive population base in the Asia-Pacific region, the burden of chronic conditions like CKD continues to rise, driving significant unmet medical needs for patients. Everest Medicines is gradually expanding its accumulated commercialization experience into the broader Asia-Pacific market. Driven by its dual-engine strategy of business development partnerships and in-house R&D, the company is poised to further unlock the value of its innovative assets, opening up new horizons for its long-term growth.Reference:1.Du X, Xiao D, Ao C, Zhang Y, Xuan J. Disease Burden of IgA Nephropathy in China. ISPOR Europe 2021. (poster/presentation).2.Yang Y, Zhang Z, Zhuo L, Chen DP, Li WG. The Spectrum of Biopsy-Proven Glomerular Disease in China: A Systematic Review. Chin Med J (Engl). 2018;131(6):731–735. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Reno, Nevada--(ACN Newswire via SeaPRwire.com - June 16, 2026) - Scandium International Mining Corp. (TSXV: SCY) (OTC Pink: SCYYF) ("Scandium International" or the "Company") is pleased to announce that Scandium International's wholly-owned subsidiary, EMC Metals Australia Pty Ltd ("EMC") has initiated an update of the Definitive Feasibility Study ("DFS") titled "Feasibility Study - Nyngan Scandium Project", dated May 4, 2016, at its Nyngan Scandium Project in New South Wales. The DFS update will be undertaken by Lycopodium Limited, headquartered in Perth, Australia, who completed the original DFS in 2016 and will reflect capital and operational efficiencies as well as potential to high-grade and customer requirements."We are very pleased to have initiated an update of the Definitive Feasibility Study for the Nyngan Scandium Project after the announcement of the grant of the Mining License in October 2025," said Peter Evensen, Chief Executive Officer. "We look forward to working with Lycopodium as we continue to develop the Nyngan Scandium project. The company is fully funded to complete the DFS update, marking an important milestone on the path toward construction and eventual production, consistent with the Project's design parameters."The update of the DFS will update the capital and operating costs and will not change the basic parameters of the existing DFS, which remain positive:is designed as a small surface mining operation recovering approximately 75,000t of limonite ore from the resource per year.delivers an average limonite scandium head grade to the mill facility over 20 years is 409ppm (before potential high-grading initiatives).includes a project development and commissioning schedule comprising a one-year construction period, and a total 24-month ramp-up period to reach nameplate capacity of 75,000 tonnes per year ore throughput and approximately 38,500 kg of scandium oxide product per year, grading 98 to 99.9% Sc₂O₃.provides a 20-year mine life at nameplate capacity, using less than 20% of the total Mineral Resource Estimate.Mr. Evensen continued: "The benefits of scandium have been known for several years; however, until now there has not been a reliable and abundant potential supply source of scandium outside of China and Russia or dependent on other commodity prices as a by-product.The Western world has made it a strategic priority to develop robust critical mineral supply chains that are not dependent on a single nation as a pinch point.The shovel-ready Nyngan Scandium Project is prepared to meet western demand for scandium in existing applications and emerging uses under development including semiconductors, solid-state batteries, and defense applications."The information in this news release has been reviewed and approved by John Thompson, BE, FAusIMM, Vice-President of Project Development, who is a Qualified Person as that term is defined in National Instrument 43-101.For inquiries to Scandium International Mining Corp, please contact:Peter Evensen, President and CEOTel: (775) 355-9500Harry de Jonge, ControllerTel: (702) 703-0178Email: info@scandiummining.comCautionary Note Regarding Forward-Looking InformationThis news release includes certain information that may be deemed "forward-looking information". Forward-looking information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "believe", "continue", "plans" or similar terminology, or negative connotations thereof. All information in this release, other than information of historical facts, general future plans and objectives for the Company and the Nyngan Scandium Project, are forward-looking information that involve various risks and uncertainties. Although the Company believes that the expectations expressed in such forward-looking information are based on reasonable assumptions, such expectations are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking information.For more information on the Company and the key assumptions, risks and challenges with respect to the forward-looking information discussed herein, and about our business in general, investors should review the Company's most recently filed annual information form, and other continuous disclosure filings which are available at www.scandiummining.com Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301583 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月16日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（HKEX 1952.HK），宣佈與Dimerix Limited（以下簡稱「Dimerix」）達成獨家商業化授權許可協議，獲得DMX-200在大中華區（包括中國大陸、中國香港、中國澳門和中國台灣地區）、韓國及若干東南亞國家（包括新加坡、馬來西亞、泰國、印尼、越南和菲律賓）的臨床開發及商業化權益。此次合作將進一步優化雲頂新耀腎科產品佈局，提升管線協同效率，強化公司在腎臟及自身免疫疾病領域的戰略地位。根據協議，雲頂新耀將向Dimerix支付1,000萬美元的首付款，以及最高不超過3,000萬美元的開發與註冊里程碑款和最高不超過3億美元的商業化里程碑款。此外，Dimerix還將根據DMX-200在授權區域內未來年度淨銷售額獲得10%至15%的分級特許權使用費。DMX-200是一種趨化因數受體2（CCR2）的小分子抑制劑，目前正在開展用於治療局灶節段性腎小球硬化（FSGS）的全球關鍵性III期臨床研究ACTION3。據公開資料顯示，DMX-200已獲得美國食品藥品監督管理局（FDA）和歐洲藥品管理局（EMA）的孤兒藥資格。雲頂新耀董事會主席吳以芳表示：「此次與Dimerix達成合作，是公司持續拓展腎病領域產品組合的重要舉措。長期以來，中國FSGS患者缺乏針對性治療，存在顯著的未滿足臨床需求。DMX-200全球關鍵性III期臨床研究的中期分析結果積極，顯示出其開發前景廣闊，有望為患者提供新的治療選擇，並填補國內FSGS治療空白。依託公司成熟的臨床開發、註冊及商業化能力，我們將加快推動DMX-200在中國及亞太市場的開發與上市進程，並探索其在其他腎小球疾病中的應用潛力。我們期待與Dimerix緊密合作，共同將這一創新療法帶給更多患者。」Dimerix首席執行官兼董事總經理Nina Webster博士表示：「我們非常高興與雲頂新耀達成合作。雲頂新耀在罕見腎病領域擁有深厚的專業經驗，並具備覆蓋大中華區、韓國及東南亞市場的成熟商業化能力。此次合作將顯著提升DMX-200在亟需治療的患者群體中的可及性。憑藉在授權區域的豐富經驗與資源，雲頂新耀有望充分釋放DMX-200的臨床與商業潛力。與此同時，Dimerix將持續推進全球註冊性臨床專案，致力於為股東創造長期價值，並為全球FSGS患者帶來切實可及的治療希望。」全球關鍵性III期臨床研究ACTION3（Angiotensin II Type 1 Receptor & Chemokine Receptor 2 Targets for Inflammatory Nephrosis）是一項多中心、隨機、雙盲、安慰劑對照臨床研究，旨在評估DMX-200聯合穩定劑量血管緊張素II受體阻滯劑（ARB）治療局灶節段性腎小球硬化（FSGS）患者的療效和安全性。在接受穩定劑量ARB治療的基礎上，受試者按隨機分組接受DMX-200（120 mg，每日兩次）或安慰劑治療。ACTION3研究設計納入兩次預設中期分析，分別評估蛋白尿和腎功能（估算腎小球濾過率斜率）等關鍵指標。目前，該研究已完成全球333例患者入組。2024年初公佈的中期分析積極結果顯示，DMX-200在降低蛋白尿方面顯著優於安慰劑。截至目前，獨立數據監查委員會已完成8次審查，最近一次於2026年6月進行，未發現任何安全性問題；且外部統計學盲態評估顯示研究仍具備充足效能（>90%），有望在研究結束時驗證DMX-200對蛋白尿的顯著改善。FSGS是一種罕見且嚴重的腎臟疾病，其主要病理特徵為腎小球部分區域出現進行性硬化（瘢痕形成），導致蛋白尿和腎功能逐漸下降，並最終可能進展為終末期腎病。當前臨床治療主要依賴非特異性的免疫抑制和支持性療法。根據慢性腎臟病流行病學模型估算，中國局灶節段性腎小球硬化的理論患病人群規模可能達到約50-100萬人1,2。相比於單一產品授權，此次合作更被業內視為雲頂新耀持續深化腎病領域佈局的重要一步。近年來，公司已圍繞IgA腎病、慢性腎臟病等領域持續構建腎科產品矩陣，其中包括耐賦康(R)、EVER001（希佈替尼）、MT1013、倍捷欣(R)（MIL62）等。DMX-200的引入不僅有望填補國內FSGS創新治療領域的空白，也將進一步豐富雲頂新耀的腎科管線梯隊，與現有產品及研發專案形成協同效應，推動其腎病佈局向更廣泛的慢性腎臟病領域延伸。與此同時，此次合作覆蓋大中華區、韓國及東南亞多個核心市場，也進一步體現出雲頂新耀持續完善亞太區域商業化網路的戰略方向。相關區域人口基數龐大，慢性腎臟病等慢病負擔持續上升，患者未滿足醫療需求顯著。雲頂新耀正在將其積累的商業化經驗逐步拓展至更廣闊的亞太市場，隨著「BD合作+自研」雙輪驅動模式的持續推進，雲頂新耀有望進一步釋放創新資產價值，為其長期增長打開新的想像空間。參考文獻：1.Du X, Xiao D, Ao C, Zhang Y, Xuan J. Disease Burden of IgA Nephropathy in China. ISPOR Europe 2021. (poster/presentation).2.Yang Y, Zhang Z, Zhuo L, Chen DP, Li WG. The Spectrum of Biopsy-Proven Glomerular Disease in China: A Systematic Review. Chin Med J (Engl). 2018;131(6):731–735. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com